Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Immtech International has selected a tablet formulation of DB289 for phase III studies in infectious diseases, following a safety trial comparing three different formulations of the drug candidate.
Subscribe to our email newsletter
The safety study’s objective was to compare the bioavailability of the current capsule formulation to two new formulations in pressed tablets. The results showed that the pressed tablets produced similar blood concentrations when compared to the capsule formulation and that the tablet formulations yielded more consistent blood levels of the active drug that is formed in the body from DB289.
The chosen formulation of DB289, the company’s first oral drug candidate, will be used in pivotal phase III studies in trypanosomiasis and pneumocystis pneumonia (PCP), as well as for commercialization.
The advantage of the pressed tablet is that it is less expensive to manufacture and more stable in conditions with high temperatures and humidity, such as those found in certain countries in sub-Sahara Africa, South America, and Asia.